Stock SYNERON MEDICAL LTD.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Syneron Medical Ltd.

Equities

IL0010909351

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Syneron Medical : Candela Completes Previously Announced Transaction with Funds Advised by Apax Partners and Becomes a Private Company
PR
Syneron Medical : Candela Announces Shareholder Approval of Proposed Acquisition by Funds Advised by Apax Partners
PR
Syneron Medical : Research Reports Coverage on Medical Equipment Stocks -- Avinger, ViewRay, Align Technology, and Syneron Medical
PR
Syneron Medical : Reports First Quarter 2017 Revenue of $66.9 Million
PR
Syneron Medical : Candela Announces End of Go-Shop Period
PR
Syneron Medical : Apax to buy Israeli aesthetic device firm Syneron for $397 million
RE
Syneron Medical : Candela Announces Agreement to be Acquired by Funds advised by Apax Partners for $11.00/share in Cash, Representing an Approximate Value of $397 Million
PR
Apax eyes IPO for investment house Psagot in Tel Aviv - source
RE
Syneron Medical : Apax close to $500 million deal to buy Israel's Syneron - reports
RE
Syneron Medical : Candela Announces CE Mark for CO2RE® Intima
PU
Syneron Medical Ltd. : Announces Availability of its Annual Report on Form 20-F through its Website
PR
Syneron Medical : Reports Fourth Quarter 2016 Revenue of $82.9 Million and Full Year 2016 Revenue $298.1 Million
PU
Syneron Medical : to Participate in Leerink Partners 6th Annual Global Healthcare Conference
PR
Syneron Medical : Strengthens Senior Management Team with Appointment of Chief Human Resources Officer
PU
Syneron Medical : to Report Fourth Quarter and Full Year 2016 Financial Results on February 15, 2017
PR
Syneron Medical : to Participate in the Canaccord Genuity Medical Technologies and Diagnostics Forum
PR
Syneron Medical : Reports Third Quarter 2016 Revenue of $71.5 Million
PR
Syneron Medical : Candela Announces FDA Clearance Of Profound™ SubQ To Improve The Appearance Of Cellulite, As Supported By Long Term Data
PU
Syneron Medical : Candela Announces FDA Clearance Of Profound(TM) SubQ To Improve The Appearance Of Cellulite, As Supported By Long Term Data
PR
Syneron Medical : Reports Second Quarter 2016 Revenue of $75.0 Million and Non-GAAP EPS of $0.09
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Syneron Medical Ltd.